Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension.

[1]  E. Fattal,et al.  Lung toxicity of biodegradable nanoparticles. , 2014, Journal of biomedical nanotechnology.

[2]  R. Vanbever,et al.  Delivery strategies for sustained drug release in the lungs. , 2014, Advanced drug delivery reviews.

[3]  B. Forbes,et al.  Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibility. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[4]  W. Seeger,et al.  Novel and emerging therapies for pulmonary hypertension. , 2014, American journal of respiratory and critical care medicine.

[5]  W. Seeger,et al.  Algorithm of Pulmonary Arterial Hypertension , 2022 .

[6]  Nicholas W Morrell,et al.  Relevant issues in the pathology and pathobiology of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[7]  Toru Satoh,et al.  Definitions and diagnosis of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[8]  O. Sitbon,et al.  Treatment goals of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[9]  D. Riches,et al.  Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice , 2012, Nanotechnology.

[10]  T. Kissel,et al.  Controlled pulmonary drug and gene delivery using polymeric nano-carriers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Moritz Beck-Broichsitter,et al.  Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[12]  W. Seeger,et al.  Development of a biodegradable nanoparticle platform for sildenafil: formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[13]  W. Seeger,et al.  Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb Pro: formulation aspects and nanoparticle stability to nebulization. , 2012, International journal of pharmaceutics.

[14]  T. Fleming,et al.  Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. , 2011, Chest.

[15]  H. Ghofrani,et al.  Mechanisms of disease: pulmonary arterial hypertension , 2011, Nature Reviews Cardiology.

[16]  R. Löbenberg,et al.  Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Robert Langer,et al.  Nanotechnology in drug delivery and tissue engineering: from discovery to applications. , 2010, Nano letters.

[18]  W. Seeger,et al.  Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles. , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[19]  Xiaoying Wang,et al.  In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[21]  F. Grimminger,et al.  Phosphodiesterase inhibitors for the treatment of pulmonary hypertension , 2008, European Respiratory Journal.

[22]  Xiaoying Wang,et al.  Biodegradable Branched Polyesters Poly(vinyl sulfonate-covinyl alcohol)-graft Poly(d,l-lactic-coglycolic acid) as a Negatively Charged Polyelectrolyte Platform for Drug Delivery: Synthesis and Characterization , 2008 .

[23]  W. Seeger,et al.  Inhaled prostanoids in the therapy of pulmonary hypertension. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[24]  W. Seeger,et al.  Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. , 2006, Toxicology and applied pharmacology.

[25]  H. Ghofrani,et al.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.

[26]  S. Malhotra,et al.  A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. , 2006, American heart journal.

[27]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[28]  W. Seeger,et al.  Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors , 2005, Respiratory research.

[29]  W. Seeger,et al.  Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. , 2004, Journal of the American College of Cardiology.

[30]  B. Raju,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[31]  C. Ruppert,et al.  Changes in pulmonary surfactant function and composition in bleomycin-induced pneumonitis and fibrosis. , 2004, Toxicology and applied pharmacology.

[32]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[33]  W. Seeger,et al.  Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. , 2001, American journal of respiratory and critical care medicine.

[34]  W. Seeger,et al.  Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. , 2001, American journal of respiratory cell and molecular biology.

[35]  J. Winkler,et al.  Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension , 2001, Critical care medicine.

[36]  W. Seeger,et al.  Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[37]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.